Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: VPM1002 for COVID-19 Prevention in Front-Line Workers
NCT04439045Phase 3Completed
- Sponsor
- University Health Network
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing VPM1002 with Placebo (2 arms). Primary endpoint: Incidence of COVID-19 infection at 7 months. Started Jun 2020; status: completed.
02
Drugs
VPM1002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04439045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439045.